105 Higashifukai, Nagareyama-shi
Number of employees 50-99
Sales volume 1-9 Mio US $
Export content max. 10%
Year of foundation 2002
Area of business Laboratory Equipment
Bio Matrix Reseach Inc.
Since its establishment in 2002, Bio Matrix Research, Inc. (BMR) has been aiming to offer high quality services with advanced analytic precision and constant cost reduction in its DNA sequencing and microarray analysis. Next to our analytic services, we have been striving to implement monoclonal antibody production as an important pillar of our operations. The entire institute is working hard so even researchers with limited budgets can be satisfied with our high-tech analytic services and antibodies.
We are aiming to be a biotech company by researchers and for researchers. In addition to analytic services, we are engaged in a variety of Research and Development efforts, ever conscious of our responsibilities for legal compliance and social contribution, as we pursue reliable, high-quality products and services to satisfy researchers’ needs.
In order to develop our operations we are also increasingly promoting R&D in high-risk genome drug discovery (searching and focusing on target genes). We will adopt new analytic techniques that emerge from this R&D process in our analytic operations and antibody production technology to not only increase the quality and breadth of our service, but to further contribute to researchers engaged in national and international academia, in research institutions and in the discovery of new drugs.
We believe that the results of medical research should be “shared equally with all people.” Our activities in analysis and research can be seen as one way of achieving this broad offering of results, as seen in our long-term objective to contribute to the eradication of cancer. By applying the cutting-edge DNA microarray, proteome analysis and antibody-production technologies that we have accumulated thus far, we are developing methods for early cancer diagnosis and identification of target genes for anticancer drugs.